Saturday 17 October 2026
Export ZLAB’s income statement to Excel — free account
Zai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024. In the quarter to June 2026, revenue fell 3.33%, EPS fell 24.3%, free cash flow fell 84.4% and total debt rose 36.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
23.19
0.32
−1.36%
Follow ZLAB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 4 | 4 |
| (28.97%) | (22.56%) | (24.19%) | (26.91%) | ||
| (19.29%) | (14.89%) | (15.70%) | (16.81%) | ||
ROIC |
(97.69%) | (109.92%) | (132.39%) | (129.34%) | |
Return on Tangible Assets |
(28.64%) | (26.98%) | (29.74%) | (35.39%) | |
Average Days of Receivables |
70.56 | 84.17 | 43.54 | 56.50 | |
Free Cash Flow per Share |
(1.91) | (1.50) | (1.20) | (1.45) | |
Free Cash Flow |
(210.33) | (164.13) | (132.76) | (162.43) | |
Capital Expenditures |
(29.79) | (13.34) | (31.76) | (29.05) | |
| Other line items | |||||
Cash ROIC |
(11.82%) | (9.60%) | (8.11%) | (10.39%) | |
Accounts Receivable Turnover |
6.53 | 4.81 | 6.94 | 5.69 | |
Accounts Payable Turnover |
1.55 | 1.58 | 1.66 | 1.60 | |
Inventory Turnover |
3.20 | 3.33 | 2.74 | 2.57 | |
Average Days of Payables |
213.02 | 270.50 | 241.40 | 254.93 | |
Days of Inventory on Hand |
143.43 | 142.78 | 164.47 | 169.51 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
47.90% | 48.01% | 49.81% | 52.69% | |
Selling, General and Administrative Expense of Revenue |
65.03% | 60.33% | 61.61% | 62.52% | |
Share Based Compensation of Revenue |
15.16% | 14.26% | 13.97% | 12.96% | |
Interest Coverage |
(47.95) | (44.05) | (42.85) | (44.13) | |
Operating CF/Net income |
0.87 | 0.86 | 0.57 | 0.71 | |
Depreciation/Fixed assets |
0.19 | 0.20 | 0.21 | 0.22 | |
Capex/Depreciation |
(3.26) | (1.38) | (3.15) | (2.79) | |
Revenue per Share |
4.01 | 4.20 | 4.09 | 4.03 | |
Operating CF per Share |
(1.64) | (1.38) | (0.91) | (1.19) | |
Capex per Share |
(0.27) | (0.12) | (0.29) | (0.26) | |
Capex to Sales |
0.07 | 0.03 | 0.07 | 0.06 |
Columns are period end dates